Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2022 | Story NONSINDISO QWABE | Photo Thabiso Mdakana
Qwaqwa Campus vaccination drive
Andile Tshabalala and Theodore Hlalele, CSRC Qwaqwa Campus.

As the University of the Free State is encouraging staff and students to be vaccinated in order for all of us to return to campus life as we know it, the Qwaqwa Campus held its first in-person vaccination activation drive for its first and returning students. The drive was to further encourage students to vaccinate, and to keep themselves and others safe by educating themselves.

The cheerful and excited crowd of more than 100 students were gathered at the Amphitheatre on campus, where they got to know more about the COVID-19 Regulations and Required Vaccination Policy and interacted with Department of Health officials to understand more about the jabs and booster shots.

No one is forced, but everyone is encouraged

The university’s approved policy came into effect on 14 February, requiring staff and students to be vaccinated as a measure towards ensuring everyone’s smooth return to its three campuses. However, as Qwaqwa Campus Principal Dr Martin Mandew highlighted, “no one is being forced to vaccinate, but we are all strongly encouraged to do so”.

Dr Mandew said the student experience is too rich and vibrant to be confined to virtual learning. He showed students his own vaccination certificate, quoting a Zulu proverb, ‘indlela ibuzwa kwabaphambili’, which loosely translated means ‘those who have gone before you can show the way’.

“If you are not vaccinated, it will be impossible for us to enjoy face-to-face interaction again. Ask yourself: ‘If the principal is vaccinated, who am I not to be?” he said.

The lively drive also kept students entertained through live performances by local artists. 

Students could also raise pressing issues and questions with Department of Health officials – including common side effects, apathy against vaccination due to religious beliefs, the efficacy of the vaccine to protect against COVID-19, and the implementation of the UFS Vaccination Policy. 

The programme line-up also included messages of support from the Director: Student Affairs, Zoleka Dotwana, the Deputy Director of Housing and Residences, Zakhele Mdluli, and UVPERSU Vice-Chairperson, Dr Grey Magaiza.

The operating days of the on-campus vaccination site have been extended to accommodate streams of incoming students who still want to be vaccinated. 

News Archive

Researchers receive study grant for research into Congo Fever
2015-03-10

UFS researchers will be contributing significantly to the search for a vaccine against the deadly tick-borne disease known as Congo Fever.

Prof Felicity Burt from the Department of Medical Microbiology and Virology was recently awarded a research grant by the National Health Laboratory Service (NHLS) to study candidate vaccines for Crimean-Congo heamorrhagic fever (CCHF) virus and other arboviruses.

Arboviruses are viruses transmitted by mosquitoes, ticks, or other arthropods.

Prof Burt is an internationally-recognised expert on the Crimean-Congo haemorrhagic fever (CCHF). The Crimean-Congo haemorrhagic fever (CCHF) virus is a tick-borne virus that is associated with severe haemorrhagic disease in South Africa and other parts of Africa, Asia, and eastern Europe. Her interests focus on medically significant viruses that are transmitted by ticks and mosquitoes. Her research group is involved in determining the immune responses that are induced by different viral proteins.

Crimean-Congo haemorrhagic fever (CCHF) virus, a tick- borne virus found in Africa, Asia, the Balkans, and eastern Europe, causes severe viral haemorrhagic fever outbreaks.

Although a number of tick species are capable of becoming infected with CCHF virus, ticks of the genus Hyalomma, commonly referred to in SA as the “bont-legged ticks”, are the principal vector. The ticks have distinctive brown and white bands on their legs.

In February 1981, the first case of CCHF was recognised in South Africa (SA). To date, there have been nearly 200 cases of CCHF infection in SA with a 20% fatality rate. The majority of cases occurring in SA were in patients from the Northern Cape and Free State provinces.

“The funding that has been awarded will be used to profile immune responses against CCHF viral proteins, and investigate mechanisms and strategies to enhance these immune responses. We hope that the study will contribute knowledge towards the development of a vaccine against this medically significant virus.”

For more information or enquiries contact news@ufs.ac.za.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept